Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Autolus Therapeutics (AUTL) Shares Outstanding (Weighted Average) (2017 - 2025)

Historic Shares Outstanding (Weighted Average) for Autolus Therapeutics (AUTL) over the last 6 years, with Q3 2025 value amounting to $266.1 million.

  • Autolus Therapeutics' Shares Outstanding (Weighted Average) rose 2.14% to $266.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $266.1 million, marking a year-over-year increase of 2.14%. This contributed to the annual value of $255.2 million for FY2024, which is 4669.32% up from last year.
  • Per Autolus Therapeutics' latest filing, its Shares Outstanding (Weighted Average) stood at $266.1 million for Q3 2025, which was up 2.14% from $266.1 million recorded in Q2 2025.
  • Over the past 5 years, Autolus Therapeutics' Shares Outstanding (Weighted Average) peaked at $266.1 million during Q3 2025, and registered a low of $62.4 million during Q1 2021.
  • Over the past 5 years, Autolus Therapeutics' median Shares Outstanding (Weighted Average) value was $173.9 million (recorded in 2023), while the average stood at $171.0 million.
  • As far as peak fluctuations go, Autolus Therapeutics' Shares Outstanding (Weighted Average) surged by 580580795.08% in 2021, and later increased by 2.14% in 2025.
  • Quarter analysis of 5 years shows Autolus Therapeutics' Shares Outstanding (Weighted Average) stood at $72.9 million in 2021, then soared by 30.31% to $95.0 million in 2022, then skyrocketed by 83.11% to $173.9 million in 2023, then skyrocketed by 46.69% to $255.2 million in 2024, then rose by 4.3% to $266.1 million in 2025.
  • Its Shares Outstanding (Weighted Average) stands at $266.1 million for Q3 2025, versus $266.1 million for Q2 2025 and $266.1 million for Q1 2025.